Synonym
Adofen; Fluoxac; Fluoxetine; Prozac
IUPAC/Chemical Name
Benzenepropanamine, N-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-
InChi Key
RTHCYVBBDHJXIQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3
SMILES Code
CNCCC(Oc1ccc(cc1)C(F)(F)F)c2ccccc2
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Fluoxetine blocks the serotonin reuptake transporter in the presynaptic terminal, resulting in sustained levels of 5-HT in certain brain areas. Fluoxetine binds with relatively poor affinity to 5-HT, dopaminergic, adrenergic, cholinergic, muscarinic, and histamine receptors. Fluoxetine interacts to a degree with the 5-HT2C receptor; it has been suggested that this mechanism allows it to increase noradrenaline and dopamine levels in the prefrontal cortex.
In vitro activity:
Fluoxetine may have the potential for acute leukemia treatment. Fluoxetine-induced apoptosis and G-2 cell cycle arrest in the human leukemic cell line Jurkat. Fluoxetine reduced IL-2 secretion dose-dependently and could be further potentiated by σ1-R antagonist BD1047 (P < 0.05). Fluoxetine inhibited pAKT six hours post-treatment
Reference: Expert Opin Ther Targets. 2022 Dec;26(12):1087-1097. https://pubmed.ncbi.nlm.nih.gov/36620917/
In vivo activity:
Fluoxetine modulated gene expression of stress-related hormone receptors, including prolactin and melanin-concentrating hormone. These results suggest that chronic social defeat stress can induce gene expression changes associated with inflammation in the kidney of C57 BL/6 male mice, and that this inflammation can be treated with fluoxetine.
Reference: FEBS Open Bio. 2023 Jul 3. https://pubmed.ncbi.nlm.nih.gov/37400956/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
309.33
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Chomchoei C, Brimson JM, Brimson S. Repurposing fluoxetine to treat lymphocytic leukemia: Apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2022 Dec;26(12):1087-1097. doi: 10.1080/14728222.2022.2166829. Epub 2023 Jan 12. PMID: 36620917.
2. Önal HT, Yetkin D, Ayaz F. Immunostimulatory activity of fluoxetine in macrophages via regulation of the PI3K and P38 signaling pathways. Immunol Res. 2023 Jun;71(3):413-421. doi: 10.1007/s12026-022-09350-4. Epub 2022 Dec 13. PMID: 36512200; PMCID: PMC9745289.
3. Jin H, Xu G, Lu Y, Niu C, Zhang X, Kan T, Cao J, Yang X, Cheng Q, Zhang J, Dong J. Fluoxetine partially alleviates inflammation in the kidney of socially stressed male C57 BL/6 mice. FEBS Open Bio. 2023 Jul 3. doi: 10.1002/2211-5463.13670. Epub ahead of print. PMID: 37400956.
4. Musaelyan K, Horowitz MA, McHugh S, Szele FG. Fluoxetine Can Cause Epileptogenesis and Aberrant Neurogenesis in Male Wild Type Mice. Dev Neurosci. 2023 Jun 9. doi: 10.1159/000531478. Epub ahead of print. PMID: 37302394.
In vitro protocol:
1. Chomchoei C, Brimson JM, Brimson S. Repurposing fluoxetine to treat lymphocytic leukemia: Apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2022 Dec;26(12):1087-1097. doi: 10.1080/14728222.2022.2166829. Epub 2023 Jan 12. PMID: 36620917.
2. Önal HT, Yetkin D, Ayaz F. Immunostimulatory activity of fluoxetine in macrophages via regulation of the PI3K and P38 signaling pathways. Immunol Res. 2023 Jun;71(3):413-421. doi: 10.1007/s12026-022-09350-4. Epub 2022 Dec 13. PMID: 36512200; PMCID: PMC9745289.
In vivo protocol:
1. Jin H, Xu G, Lu Y, Niu C, Zhang X, Kan T, Cao J, Yang X, Cheng Q, Zhang J, Dong J. Fluoxetine partially alleviates inflammation in the kidney of socially stressed male C57 BL/6 mice. FEBS Open Bio. 2023 Jul 3. doi: 10.1002/2211-5463.13670. Epub ahead of print. PMID: 37400956.
2. Musaelyan K, Horowitz MA, McHugh S, Szele FG. Fluoxetine Can Cause Epileptogenesis and Aberrant Neurogenesis in Male Wild Type Mice. Dev Neurosci. 2023 Jun 9. doi: 10.1159/000531478. Epub ahead of print. PMID: 37302394.
1: Gram L. Fluoxetine. N Engl J Med. 1994 Nov 17;331(20):1354-61. doi: 10.1056/NEJM199411173312008. Erratum in: N Engl J Med 1995 Feb 2;332(5):343. PMID: 7935707.
2: Perez-Caballero L, Torres-Sanchez S, Bravo L, Mico JA, Berrocoso E. Fluoxetine: a case history of its discovery and preclinical development. Expert Opin Drug Discov. 2014 May;9(5):567-78. doi: 10.1517/17460441.2014.907790. Epub 2014 Apr 16. PMID: 24738878.
3: Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs. 1986 Dec;32(6):481-508. doi: 10.2165/00003495-198632060-00002. PMID: 2878798.
4: Barakat A, Hamdy MM, Elbadr MM. Uses of fluoxetine in nociceptive pain management: A literature overview. Eur J Pharmacol. 2018 Jun 15;829:12-25. doi: 10.1016/j.ejphar.2018.03.042. Epub 2018 Mar 30. PMID: 29608897.
5: Bihm B, Wilson BA. Understanding fluoxetine (Prozac). Medsurg Nurs. 1996 Feb;5(1):50-2, 56. PMID: 8696409.
6: Stokes PE. Fluoxetine: a five-year review. Clin Ther. 1993 Mar- Apr;15(2):216-43; discussion 215. PMID: 8519034.
7: Kryst J, Majcher-Maślanka I, Chocyk A. Effects of chronic fluoxetine treatment on anxiety- and depressive-like behaviors in adolescent rodents - systematic review and meta-analysis. Pharmacol Rep. 2022 Oct;74(5):920-946. doi: 10.1007/s43440-022-00420-w. Epub 2022 Sep 24. PMID: 36151445; PMCID: PMC9584991.
8: Calil HM. Fluoxetine: a suitable long-term treatment. J Clin Psychiatry. 2001;62 Suppl 22:24-9. PMID: 11599644.
9: Gleiter CH, Volz HP. Fluoxetin [Fluoxetine]. Dtsch Med Wochenschr. 1997 Apr 11;122(15):481-2. German. doi: 10.1055/s-0029-1237401. PMID: 9147940.
10: Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev. 1991 Jan;11(1):17-34. doi: 10.1002/med.2610110103. PMID: 1994152.
11: Deeks ED, Keating GM. Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs. 2008;68(8):1115-37. doi: 10.2165/00003495-200868080-00008. PMID: 18484802.
12: Messiha FS. Fluoxetine: a spectrum of clinical applications and postulates of underlying mechanisms. Neurosci Biobehav Rev. 1993 Winter;17(4):385-96. doi: 10.1016/s0149-7634(05)80115-0. PMID: 8309648.
13: Tiraboschi P, Spagnoli A. Fluoxetina [Fluoxetine]. Medicina (Firenze). 1989 Apr-Jun;9(2):233-5. Italian. PMID: 2682124.
14: Creeden JF, Imami AS, Eby HM, Gillman C, Becker KN, Reigle J, Andari E, Pan ZK, O'Donovan SM, McCullumsmith RE, McCullumsmith CB. Fluoxetine as an anti- inflammatory therapy in SARS-CoV-2 infection. Biomed Pharmacother. 2021 Jun;138:111437. doi: 10.1016/j.biopha.2021.111437. Epub 2021 Feb 25. PMID: 33691249; PMCID: PMC7904450.
15: Lam RW, Wong HK, Kumarsing RA, Chua AN, Ho RC, McIntyre RS, Ho CS. Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression. Transl Psychiatry. 2022 Aug 20;12(1):339. doi: 10.1038/s41398-022-02083-w. PMID: 35987907; PMCID: PMC9392792.
16: Crundwell JK. Fluoxetine and suicidal ideation--a review of the literature. Int J Neurosci. 1993 Jan;68(1-2):73-84. doi: 10.3109/00207459308994262. PMID: 8063517.
17: Tacke U. Fluoxetine: an alternative to the tricyclics in the treatment of major depression? Am J Med Sci. 1989 Aug;298(2):126-9. doi: 10.1097/00000441-198908000-00010. PMID: 2669476.
18: Pary R, Tobias C, Lippmann S. Fluoxetine: prescribing guidelines for the newest antidepressant. South Med J. 1989 Aug;82(8):1005-9. PMID: 2669150.
19: Nguyen T, Middleton RK. Fluoxetine in bulimia. DICP. 1991 Mar;25(3):254-6. PMID: 2028633.
20: Slywka S, Hart LL. Fluoxetine in alcoholism. Ann Pharmacother. 1993 Sep;27(9):1066-7. PMID: 8219441.
